表紙
市場調査レポート

がんCD抗原阻害剤の市場とパイプライン分析 (2015年)

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 338400
出版日 ページ情報 英文 600 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
がんCD抗原阻害剤の市場とパイプライン分析 (2015年) Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
出版日: 2015年08月27日 ページ情報: 英文 600 Pages
概要

世界各国の製薬企業で現在、がんのCD (表面抗原) 向け阻害剤の治験が進行しており、その中には上市にまで漕ぎ付けた製品もあります。製造コストの高さが目下の課題ですが、今後の研究開発の進展により、その問題もいずれ解決されると期待されています。

当レポートでは、がん治療用のCD抗原阻害剤の治験状況について分析し、CD抗原の概略や、全体的な製品開発状況、抗原別の詳細な治験進行状況、上市済み製品の状況などを調査・考察すると共に、主要企業のプロファイルなどの情報も盛り込んでお届けいたします。

第1章 CD抗原の概略

第2章 CD抗原の分類

第3章 CD抗原がん治療薬の機序

第4章 がんCD抗原療法の市場の概要

  • 現在のシナリオ
  • がんCD抗原阻害剤のパイプライン製品の概要

第5章 CD抗原がん市場の動向

  • 良好な市場指標
  • 商業化に際しての課題

第6章 CD抗原がん治療薬の将来展望

第7章 がんCD抗原阻害剤の治験パイプライン:企業別・適応症別・相 (フェーズ) 別

  • 第I/II相

第8章 がんCD3抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第9章 がんCD4抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第II相

第10章 がんCD9抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第11章 がんCD11抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第12章 がんCD19抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相〜第II相

第13章 がんCD20抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜第III相
  • 上市済み製品に関する治験上の考察

第14章 がんCD22抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第II相〜第III相

第15章 がんCD26抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第I/II相

第16章 がんCD27抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜第I/II相

第17章 がんCD28抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第18章 がんCD29抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第19章 がんCD33抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相〜第I/II相
  • 上市済み製品に関する治験上の考察

第20章 がんCD37抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相〜第II相

第21章 がんCD38抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜登録前

第22章 がんCD40抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相

第23章 がんCD44抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第24章 がんCD45抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第25章 がんCD47抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第I相

第26章 がんCD52抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜前臨床
  • 上市済み製品に関する治験上の考察

第27章 がんCD55抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第28章 がんCD56抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第29章 がんCD66抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第30章 がんCD70抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相

第31章 がんCD74抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第I/II相

第32章 がんCD80抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相

第33章 がんCD95抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第34章 がんCD98抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相

第35章 がんCD100抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相

第36章 がんCD117抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第III相
  • 上市済み製品に関する治験上の考察

第37章 がんCD135抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第III相
  • 上市済み製品に関する治験上の考察

第38章 がんCD137抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第39章 がんCD152抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 上市済み製品に関する治験上の考察

第40章 がんCD200抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床

第41章 がんCD223抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜第I相

第42章 がんCD227抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相〜第II相

第43章 がんCD246抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第II相
  • 上市済み製品に関する治験上の考察

第44章 がんCD248抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第II相

第45章 がんCD274抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 研究段階〜第III相
  • 上市済み製品に関する治験上の考察

第46章 がんCD276抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相

第47章 がんCD279抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 第I相〜第II相
  • 上市済み製品に関する治験上の考察

第48章 複数のがんCD抗原阻害剤の治験パイプライン:企業別・適応症別・相別

  • 前臨床〜第III相
  • 上市済み製品に関する治験上の考察

第49章 中止・延期された治験に関する考察:がんCD抗原阻害剤の場合

  • 治験報告が出されていないもの
  • 治験が中止されたもの
  • 市場から退出したもの
  • 治験が中断されたもの

第50章 競争環境

  • Alexion Pharmaceuticals
  • ARIAD Pharmaceuticals
  • AryoGen Biopharma
  • AXXO
  • Bayer HealthCare
  • Biocad
  • Biogen
  • Biotecnol Inc.
  • Bristol-Myers Squibb
  • 中外製薬
  • Dr Reddy's Laboratories
  • エーザイ
  • Emergent BioSolutions
  • Genmab
  • ImmunoGen
  • Intas Biopharmaceuticals
  • MacroGenics
  • MedImmune
  • Merck
  • Novartis
  • 小野薬品工業
  • Onyx Pharmaceuticals
  • Pfizer
  • PROBIOMED
  • Roche
  • UCB
  • Xencor

図表一覧

目次

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient's patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

CD Antigens Segments in Report:

CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52, CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279

"Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" Report Highlight:

  • Nomenclature & Classification of CD Antigens
  • Mechanism of CD Antigen Cancer Therapeutics
  • Cancer CD Antigen Therapy Market Overview
  • Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs
  • Marketed Cancer CD Antigen Inhibitors: 27 Drugs
  • Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs
  • Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs
  • Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

Table of Contents

1. Introduction to CD Antigens

2. Nomenclature & Classification of CD Antigens

3. Mechanism of CD Antigen Cancer Therapeutics

4. Cancer CD Antigen Therapy Market Overview

  • 4.1 Current Scenario
  • 4.2 Cancer CD Antigen Inhibitors Pipeline Overview

5. CD Antigen Cancer Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Commercialization Challenges

6. CD Antigen Cancer Therapeutics Future Prospects

7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 7.1 Phase-I/II

8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 8.1 Preclinical till Phase-II

9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 9.1 Phase-II

10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 10.1 Preclinical

11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 11.1 Preclinical

12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1 Phase-I till Phase-II

13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 13.1 Research till Phase-III
  • 13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 14.1 Phase-II till Phase-III

15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 15.1 Preclinical till Phase-I/II

16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 16.1 Research till Phase-I/II

17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 17.1 Preclinical

18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 18.1 Preclinical

19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 19.1 Phase-I till Phase-I/II
  • 19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 20.1 Phase-I till Phase-II

21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 21.1 Research till Preregistration

22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 22.1 Phase-I

23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 23.1 Preclinical

24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 24.1 Preclinical till Phase-II

25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 25.1 Preclinical till Phase-I

26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 26.1 Research till Preclinical
  • 26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 27.1 Preclinical till Phase-II

28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 28.1 Preclinical till Phase-II

29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 29.1 Preclinical till Phase-II

30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 30.1 Phase-I

31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 31.1 Preclinical till Phase-I/II

32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 32.1 Preclinical till Phase-II

33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 33.1 Preclinical

34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 34.1 Phase-I

35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 35.1 Phase-I

36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 36.1 Preclinical till Phase-III
  • 36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 37.1 Preclinical till Phase-III
  • 37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 38.1 Preclinical

39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 40.1 Preclinical

41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 41.1 Research till Phase-I

42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 42.1 Phase-I till Phase-II

43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 43.1 Preclinical till Phase-II
  • 43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 44.1 Phase-II

45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 45.1 Research till Phase-III
  • 45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 46.1 Phase-I

47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 47.1 Phase-I till Phase-II
  • 47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 48.1 Preclinical till Phase-III
  • 48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight

  • 49.1 No Development Reported
  • 49.2 Discontinued
  • 49.3 Market Withdrawal
  • 49.4 Suspended

50. Competitive Landscape

  • 50.1 Alexion Pharmaceuticals
  • 50.2 ARIAD Pharmaceuticals
  • 50.3 AryoGen Biopharma
  • 50.4 AXXO
  • 50.5 Bayer HealthCare
  • 50.6 Biocad
  • 50.7 Biogen
  • 50.8 Biotecnol Inc.
  • 50.9 Bristol-Myers Squibb
  • 50.10 Chugai Pharmaceutical
  • 50.11 Dr Reddy's Laboratories
  • 50.12 Eisai Co Ltd
  • 50.13 Emergent BioSolutions
  • 50.14 Genmab
  • 50.15 ImmunoGen
  • 50.16 Intas Biopharmaceuticals
  • 50.17 MacroGenics
  • 50.18 MedImmune
  • 50.19 Merck
  • 50.20 Novartis
  • 50.21 Ono Pharmaceutical
  • 50.22 Onyx Pharmaceuticals
  • 50.23 Pfizer
  • 50.24 PROBIOMED
  • 50.25 Roche
  • 50.26 UCB
  • 50.27 Xencor

List of Figures

  • Figure 1-1: Functions of CD Antigens
  • Figure 1-2: Properties of CD Antigens
  • Figure 2-1: Types of WBC
  • Figure 2-2: Classification of CD Antigens
  • Figure 3-1: Important Features of CD Antigens
  • Figure 3-2: Mechanism of Rituximab
  • Figure 3-3: Mechanism of Brentuximab Vedotin
  • Figure 3-4: Mechanism of Blinatumomab
  • Figure 3-5: Mechanism of Ibritumomab Tiuxetan
  • Figure 3-6: Mechanism of Tositumomab Iodine 131
  • Figure 3-7: Mechanism of Catumaxomab
  • Figure 4-1: Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-2: Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-3: Cancer CD3 Antigen Pipeline by Phase (%), 2015
  • Figure 4-4: Cancer CD3 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-5: Cancer CD19 Antigen Pipeline by Phase (%), 2015
  • Figure 4-6: Cancer CD19 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-7: Cancer CD20 Antigen Pipeline by Phase (%), 2015
  • Figure 4-8: Cancer CD20 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-9: Cancer CD22 Antigen Pipeline by Phase (%), 2015
  • Figure 4-10: Cancer CD22 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-11: Cancer CD26 Antigen Pipeline by Phase (%), 2015
  • Figure 4-12: Cancer CD26 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-13: Cancer CD27 Antigen Pipeline by Phase (%), 2015
  • Figure 4-14: Cancer CD27 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-15: Cancer CD33 Antigen Pipeline by Phase (%), 2015
  • Figure 4-16: Cancer CD33 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-17: Cancer CD38 Antigen Pipeline by Phase (%), 2015
  • Figure 4-18: Cancer CD38 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-19: Cancer CD45 Antigen Pipeline by Phase (%), 2015
  • Figure 4-20: Cancer CD45 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-21: Cancer CD47 Antigen Pipeline by Phase (%), 2015
  • Figure 4-22: Cancer CD47 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-23: Cancer CD52 Antigen Pipeline by Phase (%), 2015
  • Figure 4-24: Cancer CD52 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-25: Cancer CD55 Antigen Pipeline by Phase (%), 2015
  • Figure 4-26: Cancer CD55 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-27: Cancer CD56 Antigen Pipeline by Phase (%), 2015
  • Figure 4-28: Cancer CD56 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-29: Cancer CD66 Antigen Pipeline by Phase (%), 2015
  • Figure 4-30: Cancer CD66 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-31: Cancer CD74 Antigen Pipeline by Phase (%), 2015
  • Figure 4-32: Cancer CD74 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-33: Cancer CD80 Antigen Pipeline by Phase (%), 2015
  • Figure 4-34: Cancer CD80 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-35: Cancer CD117 Antigen Pipeline by Phase (%), 2015
  • Figure 4-36: Cancer CD117 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-37: Cancer CD135 Antigen Pipeline by Phase (%), 2015
  • Figure 4-38: Cancer CD135 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-39: Cancer CD223 Antigen Pipeline by Phase (%), 2015
  • Figure 4-40: Cancer CD223 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-41: Cancer CD227 Antigen Pipeline by Phase (%), 2015
  • Figure 4-42: Cancer CD227 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-43: Cancer CD246 Antigen Pipeline by Phase (%), 2015
  • Figure 4-44: Cancer CD246 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-45: Multiple Cancer CD Antigen Pipeline by Phase (%), 2015
  • Figure 4-46: Multiple Cancer CD Antigen Pipeline by Phase (Number), 2015
  • Figure 4-47: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (%), 2015
  • Figure 4-48: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (Number), 2015
  • Figure 4-49: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (%), 2015
  • Figure 4-50: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (Number), 2015
  • Figure 4-51: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (%), 2015
  • Figure 4-52: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (Number), 2015
  • Figure 5-1: Favorable Market Features
  • Figure 5-2: Cancer CD Antigen Inhibitors Commercialization Challenges
  • List of Tables
  • Table 5-1: Different CD Antigens used for Hematological Malignancies
Back to Top